Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?

Autores
Ferrari, Alejandro; Ledesma, Martin Manuel; Leoni, Juliana
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Since 1993, Heavy Chain Antibodies (HCAbs) have been in the eye of a biotechnological storm. Ever since their discovery, several research groups as well as biomedical foundations and pharmaceutical companies have devoted their efforts to produce recombinant variable fragments (VHH) specific for therapeutic targets, based on HCAbs. They were supposed to be nonimmunogenic, and the smallest peptides with specific binding capacity and nanomolar affinity, and therefore expected to be an endless source of bio-drugs. In this context, a camelid-fever extended worldwide along with a sudden interest in breeding, selling and buying these animals. However, very few research groups showed interest in the health of these species, and even fewer in the immunobiological role of HCAbs in vivo. Why do these animals bear such proteins? Why has this feature only been found in camelids and cartilaginous fish? Is there any advantage in HCAbs when compared to conventional antibodies? This review is focused on the origin of the interest scientists had for HCAbs, and is aimed to understand the reasons for the generalized cooling-down of the HCAbs fever, and the sudden regained interest on camelids? health and immune system. We here review the history of HCAbs from their discovery to the current status of the knowledge about their immune system. Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?
Fil: Ferrari, Alejandro. Consejo Nacional de Investigaciones Cienti­ficas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; Argentina
Fil: Ledesma, Martin Manuel. Consejo Nacional de Investigaciones Cienti­ficas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; Argentina
Fil: Leoni, Juliana. Consejo Nacional de Investigaciones Cienti­ficas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; Argentina
Materia
Heavy Chain
Antibodies
Polyclonal
Camelids
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/6574
Acceder
id CONICETDig_3d9df21250a225ce7c35e3fab6b96e7d
oai_identifier_str oai:ri.conicet.gov.ar:11336/6574
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?Ferrari, AlejandroLedesma, Martin ManuelLeoni, JulianaHeavy ChainAntibodiesPolyclonalCamelidshttps://purl.org/becyt/ford/4.3https://purl.org/becyt/ford/4Since 1993, Heavy Chain Antibodies (HCAbs) have been in the eye of a biotechnological storm. Ever since their discovery, several research groups as well as biomedical foundations and pharmaceutical companies have devoted their efforts to produce recombinant variable fragments (VHH) specific for therapeutic targets, based on HCAbs. They were supposed to be nonimmunogenic, and the smallest peptides with specific binding capacity and nanomolar affinity, and therefore expected to be an endless source of bio-drugs. In this context, a camelid-fever extended worldwide along with a sudden interest in breeding, selling and buying these animals. However, very few research groups showed interest in the health of these species, and even fewer in the immunobiological role of HCAbs in vivo. Why do these animals bear such proteins? Why has this feature only been found in camelids and cartilaginous fish? Is there any advantage in HCAbs when compared to conventional antibodies? This review is focused on the origin of the interest scientists had for HCAbs, and is aimed to understand the reasons for the generalized cooling-down of the HCAbs fever, and the sudden regained interest on camelids? health and immune system. We here review the history of HCAbs from their discovery to the current status of the knowledge about their immune system. Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?Fil: Ferrari, Alejandro. Consejo Nacional de Investigaciones Cienti­ficas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; ArgentinaFil: Ledesma, Martin Manuel. Consejo Nacional de Investigaciones Cienti­ficas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; ArgentinaFil: Leoni, Juliana. Consejo Nacional de Investigaciones Cienti­ficas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; ArgentinaResearch Trends2013-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/6574Ferrari, Alejandro; Ledesma, Martin Manuel; Leoni, Juliana; Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?; Research Trends; Current Trends in Immunology; 14; 6-2013; 23-330972-4567enginfo:eu-repo/semantics/altIdentifier/url/http://www.researchtrends.net/tia/abstract.asp?in=0&vn=14&tid=36&aid=4288&pub=2013&type=3info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:17:26Zoai:ri.conicet.gov.ar:11336/6574instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:17:27.239CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?
title Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?
spellingShingle Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?
Ferrari, Alejandro
Heavy Chain
Antibodies
Polyclonal
Camelids
title_short Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?
title_full Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?
title_fullStr Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?
title_full_unstemmed Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?
title_sort Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?
dc.creator.none.fl_str_mv Ferrari, Alejandro
Ledesma, Martin Manuel
Leoni, Juliana
author Ferrari, Alejandro
author_facet Ferrari, Alejandro
Ledesma, Martin Manuel
Leoni, Juliana
author_role author
author2 Ledesma, Martin Manuel
Leoni, Juliana
author2_role author
author
dc.subject.none.fl_str_mv Heavy Chain
Antibodies
Polyclonal
Camelids
topic Heavy Chain
Antibodies
Polyclonal
Camelids
purl_subject.fl_str_mv https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
dc.description.none.fl_txt_mv Since 1993, Heavy Chain Antibodies (HCAbs) have been in the eye of a biotechnological storm. Ever since their discovery, several research groups as well as biomedical foundations and pharmaceutical companies have devoted their efforts to produce recombinant variable fragments (VHH) specific for therapeutic targets, based on HCAbs. They were supposed to be nonimmunogenic, and the smallest peptides with specific binding capacity and nanomolar affinity, and therefore expected to be an endless source of bio-drugs. In this context, a camelid-fever extended worldwide along with a sudden interest in breeding, selling and buying these animals. However, very few research groups showed interest in the health of these species, and even fewer in the immunobiological role of HCAbs in vivo. Why do these animals bear such proteins? Why has this feature only been found in camelids and cartilaginous fish? Is there any advantage in HCAbs when compared to conventional antibodies? This review is focused on the origin of the interest scientists had for HCAbs, and is aimed to understand the reasons for the generalized cooling-down of the HCAbs fever, and the sudden regained interest on camelids? health and immune system. We here review the history of HCAbs from their discovery to the current status of the knowledge about their immune system. Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?
Fil: Ferrari, Alejandro. Consejo Nacional de Investigaciones Cienti­ficas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; Argentina
Fil: Ledesma, Martin Manuel. Consejo Nacional de Investigaciones Cienti­ficas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; Argentina
Fil: Leoni, Juliana. Consejo Nacional de Investigaciones Cienti­ficas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral "Profesor R. A. Margni"; Argentina
description Since 1993, Heavy Chain Antibodies (HCAbs) have been in the eye of a biotechnological storm. Ever since their discovery, several research groups as well as biomedical foundations and pharmaceutical companies have devoted their efforts to produce recombinant variable fragments (VHH) specific for therapeutic targets, based on HCAbs. They were supposed to be nonimmunogenic, and the smallest peptides with specific binding capacity and nanomolar affinity, and therefore expected to be an endless source of bio-drugs. In this context, a camelid-fever extended worldwide along with a sudden interest in breeding, selling and buying these animals. However, very few research groups showed interest in the health of these species, and even fewer in the immunobiological role of HCAbs in vivo. Why do these animals bear such proteins? Why has this feature only been found in camelids and cartilaginous fish? Is there any advantage in HCAbs when compared to conventional antibodies? This review is focused on the origin of the interest scientists had for HCAbs, and is aimed to understand the reasons for the generalized cooling-down of the HCAbs fever, and the sudden regained interest on camelids? health and immune system. We here review the history of HCAbs from their discovery to the current status of the knowledge about their immune system. Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?
publishDate 2013
dc.date.none.fl_str_mv 2013-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/6574
Ferrari, Alejandro; Ledesma, Martin Manuel; Leoni, Juliana; Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?; Research Trends; Current Trends in Immunology; 14; 6-2013; 23-33
0972-4567
url http://hdl.handle.net/11336/6574
identifier_str_mv Ferrari, Alejandro; Ledesma, Martin Manuel; Leoni, Juliana; Heavy Chain Antibodies: The panacea for human health or just incomplete proteins?; Research Trends; Current Trends in Immunology; 14; 6-2013; 23-33
0972-4567
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.researchtrends.net/tia/abstract.asp?in=0&vn=14&tid=36&aid=4288&pub=2013&type=3
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Research Trends
publisher.none.fl_str_mv Research Trends
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614128065314816
score 13.070432

Publicaciones similares